Novocalmin (Metamizole Sodium)

Metamizole sodium works by inhibiting cyclooxygenase enzymes, which lowers the production of prostaglandins—substances that mediate pain, fever, and inflammation. By reducing prostaglandin levels, the drug provides analgesic and antipyretic effects, helping to alleviate discomfort and lower elevated body temperature.

The appropriate dose of Novocalmin is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and clinical response. Dosage may vary, and the prescriber will provide specific instructions that should be followed exactly as written.

Safety of metamizole sodium during pregnancy or lactation has not been definitively established. Healthcare providers usually weigh the potential benefits against possible risks before prescribing it to pregnant or nursing mothers. Patients should discuss their individual situation with a qualified medical professional.

To request Novocalmin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Novocalmin (metamizole sodium) belongs to the pyrazolone class, offering strong analgesic and antipyretic effects similar to non‑steroidal anti‑inflammatory drugs (NSAIDs) but with a different safety profile. Unlike many NSAIDs, it has a lower risk of gastrointestinal ulceration but carries a rare risk of agranulocytosis, which requires regular blood monitoring.

Novocalmin should be stored at room temperature, below 25 °C, in its original packaging. It must be kept away from moisture, direct sunlight, and sources of heat to maintain stability and potency throughout its shelf life.

Novocalmin is supplied as a rectal dosage form. The medication is inserted into the rectum, where it is absorbed through the mucosa, providing systemic analgesic and antipyretic effects. Administration technique and dosage volume are determined by the prescribing clinician.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white blood cells, and severe skin reactions such as Stevens‑Johnson syndrome. Early detection through regular blood count monitoring and prompt discontinuation at the first sign of adverse reactions are essential to mitigate these risks.

Novocalmin should be avoided in individuals with a known hypersensitivity to metamizole or other pyrazolones, patients with existing severe blood dyscrasias, and those receiving other myelosuppressive therapies. Caution is also advised for patients with significant renal or hepatic impairment, and it is generally not recommended for children unless specifically prescribed.